Last updated: February 15, 2026
What is NDC 82009-0060?
The National Drug Code (NDC) 82009-0060 is identified as Botulinum Neurotoxin Type A. It is marketed by Evolvet under the brand Daxxify (also known as daxibotulinumtoxinA-lanm). Approved by the FDA in 2022 for the treatment of glabellar lines, Daxxify is a long-acting botulinum toxin with 6-9 month duration, positioning it as a competitive alternative to existing botulinum toxins such as Botox, Dysport, and Xeomin.
Market Overview
Market Size and Growth Drivers
- The global botulinum toxin market was valued at approximately $4.4 billion in 2022.
- Expected compound annual growth rate (CAGR): 7-9% (2023-2028).
- Growth driven primarily by cosmetic applications, followed by therapeutic uses for conditions like cervical dystonia, spasticity, hyperhidrosis, and migraines.
- Regulatory approvals for longer-duration formulations, such as Daxxify's 6-9 month effect, enhance market potential.
Competitive Landscape
- Main competitors: Botox (Allergan), Dysport (Ipsen), Xeomin (Eli Lilly).
- Daxxify's longer duration offers significant differentiation; aligning with market demand for less frequent treatments.
Market Penetration and Adoption
- Early adoption among dermatologists and neurologists.
- Initial price points reported at $1,200 to $1,400 per treatment.
- Adoption mostly in cosmetic settings; therapeutic indications expected to expand market size.
Regulatory and Reimbursement Factors
- Reimbursement is aligned with existing botulinum treatments, with Medicare and private insurers covering procedure costs.
- Pricing negotiations and coverage varies by region and payer policies.
Price Projections Analysis
| Year |
Price per Treatment ($) |
Comments |
| 2023 |
1,200 - 1,400 |
Launch phase, early adopters, premium pricing justified by longer duration. |
| 2024 |
1,200 - 1,400 |
Slight stabilization, with potential discounts for volume or bundled treatments. |
| 2025 |
1,100 - 1,300 |
Price competition increases as other long-acting formulations enter the market. |
| 2026 |
1,000 - 1,200 |
Market saturation, price pressures, increased therapeutic indications. |
| 2027+ |
900 - 1,100 |
Increased competition and generics may pressure pricing downward; strategic value-based pricing may emerge. |
Key Factors Affecting Price Trends
- Regulatory approvals for additional indications could raise demand.
- Market penetration rate impacts pricing: higher adoption could sustain premiums longer.
- Manufacturing costs and supply chain stability influence pricing adjustments.
- Competitive activity, including new entrants or biosimilar developments, can drive prices down.
Risks and Opportunities
- Risks include faster-than-expected entry of biosimilar competitors, payer pushback on high prices, and regulatory delays for new indications.
- Opportunities involve expanding into therapeutic indications, expanding geographically, and improving customer education regarding the benefits of longer-lasting formulations.
Key Takeaways
- NDC 82009-0060 (Daxxify) operates in a rapidly growing, competitive market valued at over $4.4 billion globally.
- Early pricing ranges from $1,200 to $1,400 per treatment, with potential decreases to $900-$1,100 as market maturation occurs.
- Long-acting properties position Daxxify favorably against shorter-acting competitors, potentially influencing premium pricing.
- Market expansion into therapeutic applications and additional indications could increase both volume and price opportunities.
- Price trajectories depend significantly on competitive dynamics, reimbursement policies, and clinical adoption rates.
FAQs
1. How does Daxxify differ from Botox in terms of market potential?
Daxxify's longer duration (6-9 months) offers a competitive advantage, reducing treatment frequency and potentially garnering higher patient adherence. This could lead to increased market share in both cosmetic and therapeutic segments.
2. What are the primary factors influencing the price of NDC 82009-0060?
Pricing depends on competition, regulatory approvals, reimbursement policies, and market adoption. Longer duration treatments can command premium prices initially but may face downward pressure over time.
3. Will biosimilars impact the price of Daxxify?
Yes, biosimilars and copycat products generally exert price competition pressure once exclusivity periods end, which could lead to a decrease in prices within 3-5 years.
4. What is the significance of expanding indications for Daxxify?
Additional therapeutic indications can diversify revenue streams, increase volume, and justify premium pricing. Regulatory approval for such uses often leads to market growth.
5. How does geographic expansion influence price projections?
Entering international markets opens new revenue channels but can introduce pricing variability depending on regional economic factors, reimbursement policies, and regulatory environments.
Citations
- MarketsandMarkets. "Botulinum Toxin Market by Application, End User, and Region — Global Forecast to 2028." 2022.
- FDA. "FDA approves Daxxify for glabellar lines." 2022.
- Grand View Research. "Botulinum Toxin Market Size, Share & Trends." 2022.
- Bloomberg Terminal Data. Price range reports for Daxxify treatments in 2023.
- Analysis based on industry reports, regulatory filings, and market surveys, 2023.
[1] https://www.marketsandmarkets.com/
[2] https://www.fda.gov/
[3] https://www.grandviewresearch.com/
[4] Bloomberg Terminal internal treatment price reports.
